2 Positive Diabetes Results In patients with Type 2 diabetes, KAI-7535 achieved HbA1c reductions of up to 1.68%, outperforming dapagliflozin (Farxiga) at 1.28%, supporting its dual positioning across obesity and diabetes
A pharmacist will review your health background and discuss your goals with you personally
Stephens FB, Wall BT, Marimuthu K, Shannon CE, Constantin-Teodosiu D, Macdonald IA, Greenhaff PL
Case Study Outpatient Office
GE2 treatment significantly reduced IL-13 levels in the dorsal hippocampus compared to vehicle (main effect of treatment: F (1,44) = 5.346, p 2 = 0.106, p = 0.025